Last reviewed · How we verify
Ticagrelor-Test product
At a glance
| Generic name | Ticagrelor-Test product |
|---|---|
| Sponsor | Bio-innova Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE) (NA)
- The Study of CYP2C19 Genotype-Guided Clopidogrel Treatment Models (NA)
- Precise Antiplatelet THerapy Guided by Platelet Aggregation Function in Ischemic STROKE（PATH-STROKE） (PHASE4)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- A Genomic Approach for Clopidogrel in Caribbean Hispanics (EARLY_PHASE1)
- Ticagrelor Tablets 90 mg Relative to Originator Ticagrelor Tablets 90 mg (PHASE1)
- Guided Antiplatelet Therapy in Interventional Treatment of Intracranial Aneurysms (NA)
- Bioequivalence Study of Anplag® 90mg (Ticagrelor) Tablet & Brilinta® 90 mg (Ticagrelor) Tablet in Healthy Adult Male Pakistani Subjects Under Fasting Condition (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticagrelor-Test product CI brief — competitive landscape report
- Ticagrelor-Test product updates RSS · CI watch RSS
- Bio-innova Co., Ltd portfolio CI